+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment



Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment



International Review of Neurobiology 84: 105-131



With the anticipated increase in dementias due to the aging demographic of industrialized nations, biomarkers for neurodegenerative diseases are increasingly important as new therapies are being developed for clinical trials. Proton MR spectroscopy ((1)H MRS) appears poised to be a viable means of tracking brain metabolic changes due to neurodegenerative diseases and potentially as a biomarker for treatment effects in clinical therapeutic trials. This review highlights the body of literature investigating brain metabolic abnormalities in Alzheimer's disease, amnestic mild cognitive impairment, frontotemporal dementia, vascular dementia, Lewy body dementia, and Parkinson's disease dementia. In particular, the review addresses the viability of (1)H MRS to discriminate among dementias, to measure disease progression, and to measure the effects of pharmacological treatments. While findings to date are encouraging, more study is needed in longitudinal patterns of brain metabolic changes, correspondence with changes in clinical markers of disease progression, and sensitivity of (1)H MRS measures to treatment effects. Such developments will hopefully benefit the search for effective treatments of dementias in the twenty-first century.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260138

Download citation: RISBibTeXText

PMID: 19501715

DOI: 10.1016/S0074-7742(09)00406-1


Related references

Hydrogen Proton Magnetic Resonance Spectroscopy in Multidomain Amnestic Mild Cognitive Impairment and Vascular Cognitive Impairment Without Dementia. American Journal of Alzheimer's Disease and Other Dementias 31(5): 422-429, 2017

Using proton magnetic resonance spectroscopy to identify mild cognitive impairment. International Psychogeriatrics 24(1): 19-27, 2012

Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology 29(6): 599-609, 2007

Proton magnetic resonance spectroscopy in mild cognitive impairment and Alzheimer's disease: a preliminary study. Journal of the Medical Association of Thailand 97(4): 407-414, 2014

Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: a pilot study. Journal of Computer Assisted Tomography 31(5): 666-670, 2007

Proton magnetic resonance spectroscopy as a diagnostic biomarker in mild cognitive impairment following stroke in acute phase. Neuroreport 27(8): 559-563, 2018

Prediction of conversion from amnestic mild cognitive impairment to Alzheimer's disease using proton magnetic resonance spectroscopy. Rinsho Shinkeigaku 55(10): 709-715, 2016

Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Archives of Neurology 65(12): 1621-1628, 2008

Brain metabolism assessed via proton magnetic resonance spectroscopy in patients with amnestic or vascular mild cognitive impairment. Clinical Neurology and Neurosurgery 130(): 80-85, 2015

Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dementia and Geriatric Cognitive Disorders 30(1): 71-77, 2010

Magnetic Resonance Spectroscopy Study of Amnestic Mild Cognitive Impairment and Vascular Cognitive Impairment With No Dementia. American Journal of Alzheimer's Disease and Other Dementias 29(5): 474-481, 2013

Cognitive impairment: classification by proton magnetic resonance spectroscopy and the contributions of conventional magnetic resonance imaging. Radiologia 48(5): 301-307, 2006

Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Journal of Clinical Psychiatry 64(3): 235-242, 2003

Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment. American Journal of Alzheimer's Disease and Other Dementias 26(8): 631-636, 2012

Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a magnetic resonance spectroscopy study at 7 Tesla. Neurobiology of Aging 73: 211-218, 2018